Drug Profile
Curcumin/doxorubicin - Immix Biopharma
Alternative Names: Imx-110; polyphenol-curcuminoid/PEG-PE doxorubicin complexLatest Information Update: 19 Jul 2023
Price :
$50
*
At a glance
- Originator Immix Biopharma
- Developer BeiGene; Immix Biopharma
- Class Anthracyclines; Anti-ischaemics; Antihistamines; Antineoplastics; Antivirals; Catechols; Chemopreventatives; Cytostatic antibiotics; Doxorubicins; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Caspase 9 stimulants; Cyclo-oxygenase 2 inhibitors; Cystic fibrosis transmembrane conductance regulator modulators; DNA intercalators; HIV integrase inhibitors; Immunosuppressants; Mast cell stabilisers; NF-kappa B inhibitors; P53 gene stimulants; Phosphotransferase inhibitors; Platelet aggregation inhibitors; Protein tyrosine kinase inhibitors; STAT3 transcription factor inhibitors; Thromboxane synthase inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Soft tissue sarcoma; Solid tumours
- Preclinical Pancreatic cancer
Most Recent Events
- 17 Jul 2023 Interim adverse events and efficacy data from a phase Ib/IIa trial in Solid tumours released by Immix Biopharma
- 03 May 2023 Interim efficacy and adverse events data from a phase Ib/IIa IMMINENT-01 trial in Solid tumours (In children, In adults, In the elderly, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) released by Immix Biopharma
- 03 Feb 2023 Phase-I/II clinical trials in Solid tumours (In children, In adults, In the elderly, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Brazil (Parenteral) (NCT05840835)